Cogentix Medical, Inc. (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover. The Company's products include Urgent PC Neuromodulation System, Macroplastique Bulking Agent, Endoscopy Systems and EndoSheath Technology. The Company is also engaged in the commercialization of the Urgent PC Neuromodulation System, a device which delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). Its Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD). The Company offers 5000 and 7000 series of endoscopes, which are video endoscopy systems.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Medical Devices & Implants
- Sub-Industry: N/A
- Symbol: NYSE:UPI
- CUSIP: N/A
- Web: www.uroplasty.com/
- 50 Day Moving Avg: $1.00
- 200 Day Moving Avg: $1.00
- 52 Week Range: $1.00 - $4.00
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: Infinity
- P/E Growth: 0
- Net Margins: -31.58%
- Return on Equity: -87.33%
- Return on Assets: -60.82%
- Average Volume: 204,569 shs.
Frequently Asked Questions for Uroplasty (NYSE:UPI)
What is Uroplasty's stock symbol?
Uroplasty trades on the New York Stock Exchange (NYSE) under the ticker symbol "UPI."
How were Uroplasty's earnings last quarter?
Uroplasty, Inc. (NYSE:UPI) released its earnings results on Thursday, January, 22nd. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.04) by $0.02. The company had revenue of $6.67 million for the quarter, compared to analysts' expectations of $6.89 million. Uroplasty had a negative return on equity of 87.33% and a negative net margin of 31.58%. View Uroplasty's Earnings History.
Who are some of Uroplasty's key competitors?
Some companies that are related to Uroplasty include Stryker Corporation (SYK), Smith & Nephew SNATS (SNN), Smith & Nephew plc (SN), Glaukos Corporation (GKOS), Endologix (ELGX), RTI Surgical (RTIX), Cerus Corporation (CERS), ConforMIS (CFMS), OBALON THERPTCS (OBLN), Second Sight Medical Products (EYES), Concepta PLC (CPT), Concepta PLC (FRI), Cyberonics (CYBX), HeartWare International (HTWR), St Jude Medical (STJ) and Trivascular Technologies (TRIV).
How do I buy Uroplasty stock?
Shares of Uroplasty can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Uroplasty's stock price today?
MarketBeat Community Rating for Uroplasty (NYSE UPI)MarketBeat's community ratings are surveys of what our community members think about Uroplasty and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Uroplasty stock can currently be purchased for approximately $1.00.
Consensus Ratings for Uroplasty (NYSE:UPI) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Uroplasty (NYSE:UPI)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Uroplasty (NYSE:UPI)Earnings History by Quarter for Uroplasty (NYSE UPI)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|1/22/2015||Q3||($0.04)||($0.06)||$6.89 million||$6.67 million||View||Listen|
|10/23/2014||Q2||($0.07)||($0.05)||$6.49 million||$6.46 million||View||Listen|
|7/24/2014||Q1||($0.05)||($0.10)||$6.35 million||$6.39 million||View||Listen|
|5/15/2014||Q4 13||($0.04)||($0.05)||$6.40 million||$6.36 million||View||N/A|
|1/23/2014||Q314||($0.04)||($0.03)||$6.13 million||$6.40 million||View||Listen|
|10/24/2013||Q214||($0.05)||($0.04)||$6.09 million||$6.00 million||View||Listen|
|5/30/2013||Q4 2013||($0.04)||($0.05)||$5.59 million||$5.54 million||View||Listen|
Earnings Estimates for Uroplasty (NYSE:UPI)
Current Year EPS Consensus Estimate: $-0 EPS
Dividend History for Uroplasty (NYSE:UPI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Uroplasty (NYSE:UPI)Insider Trades by Quarter for Uroplasty (NYSE:UPI)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|1/30/2015||Brett Reynolds||CFO||Buy||5,000||$1.32||$6,600.00|| |
|1/29/2015||Kevin H Roche||Director||Buy||50,000||$1.23||$61,500.00|| |
|1/29/2015||Robert Kill||CEO||Buy||25,000||$1.26||$31,500.00|| |
|7/30/2014||Kevin H Roche||Director||Buy||10,000||$2.45||$24,500.00|| |
|7/29/2014||Kevin H Roche||Director||Buy||9,000||$2.44||$21,960.00|| |
|6/3/2014||Kevin H Roche||Director||Buy||10,000||$2.97||$29,700.00|| |
|6/2/2014||Robert Kill||CEO||Buy||13,950||$2.95||$41,152.50|| |
|3/6/2014||Susan Hartjes Holman||VP||Sell||38,000||$3.98||$151,240.00|| |
|1/29/2014||Susan Hartjes Holman||SVP||Sell||52,500||$4.59||$240,975.00|| |
|12/11/2013||Robert Patrick Maxwell||Director||Sell||3,819||$2.70||$10,311.30|| |
|8/23/2013||Brett Reynolds||CFO||Buy||8,000||$2.99||$23,920.00|| |
|8/23/2013||James Stauner||Director||Buy||8,300||$3.03||$25,149.00|| |
|8/7/2013||Robert Kill||CEO||Buy||36,050||$2.77||$99,858.50|| |
|8/6/2013||Darin Hammers||VP||Buy||6,800||$2.82||$19,176.00|| |
Headline Trends for Uroplasty (NYSE:UPI)
Latest Headlines for Uroplasty (NYSE:UPI)
Uroplasty (UPI) Chart for Wednesday, July, 26, 2017